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We studied three newly diagnosed xeroderma pig-
mentosum complementation group G patients with
markedy different clinical features. An Israeli-
Palestinian girl (XP96TA) had severe abnormal-
ities suggestive of the xeroderma pigmentosum/
Cockayne syndrome complex including sun sensitiv-
ity, neurologic and developmental impairment, and
death by age 6 y. A Caucasian girl (XP82DC) also had
severe sun sensitivity with neurologic and develop-
mental impairment and died at 5.8 y. In contrast, a
mildly affected 14-y-old Caucasian female (XP65BE)
had sun sensitivity but no neurologic abnormalities.
XP96TA, XP82DC, and XP65BE ®broblasts showed
marked reductions in post-ultraviolet cell survival and
DNA repair but these were higher in XP65BE than in
XP82DC. XP96TA ®broblasts had very low XPG
mRNA expression levels whereas XP65BE ®broblasts
had nearly normal levels. Host cell reactivation of an
ultraviolet-treated reporter assigned all three ®bro-
blast strains to the rare xeroderma pigmentosum
complementation group G (only 10 other patients
previously reported). XP96TA and XP82DC cells had
mutations in both XPG alleles that are predicted to
result in severely truncated proteins including stop
codons and two base frameshifts. The mild XP65BE
patient had an early stop codon mutation in the
paternal allele. The XP65BE maternal allele had a sin-
gle base missense mutation (G2817A, Ala874Thr) that
showed residual ability to complement xeroderma
pigmentosum complementation group G cells. These
observations agree with earlier studies demonstrating
that XPG mutations, which are predicted to lead to
severely truncated proteins in both alleles, were asso-
ciated with severe xeroderma pigmentosum/
Cockayne syndrome neurologic symptoms. Retaining
residual functional activity in one allele was associated
with mild clinical features without neurologic abnor-
malities. Key words: Cockayne syndrome/DNA repair/
host cell reactivation/molecular genetics/sun sensitivity. J
Invest Dermatol 118:972±982, 2002
X
eroderma pigmentosum (XP), Cockayne syndrome (CS),
and trichothiodystrophy are three rare autosomal recessive
inherited human disorders that are associated with impaired
nucleotide excision repair (NER) activity (Bootsma et al, 1998). XP
is characterized clinically by severe hypersensitivity to sunlight,
abnormal skin pigmentation, and a marked predisposition to skin
cancer (Kraemer and Slor, 1985; Kraemer et al, 1994).
Sunlight exposure generates DNA damage that primarily consists
of cyclobutane pyrimidine dimers and 6±4 photoproducts (Clingen
et al, 1995). This damage is normally repaired by the NER system
thereby preventing cell death, mutation, or carcinogenic trans-
formation (Wood, 1996; De Laat et al, 1999). Due to this inherited
defect in NER the rate of skin cancers in XP patients is increased
more than 1000-fold in comparison with normal individuals
(Kraemer et al, 1987; Van Steeg and Kraemer, 1999). In addition to
their skin problems, about 20% of XP patients may also develop
neurologic abnormalities. Defects in at least seven different NER
genes (XP complementation groups A±G) lead to the clinical XP
phenotype (Bootsma et al, 1998; Van Steeg and Kraemer, 1999).
An additional form, the XP variant (XP-V), also results in XP
symptoms. These patients are defective in DNA postreplication
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repair, however, and have mutations in the DNA polymerase h
gene, which is responsible for error-free bypass of ultraviolet (UV)
induced DNA damage (Johnson et al, 1999; Masutani et al, 1999).
The human XP group G (XPG) gene was identi®ed as ERCC5
(Mudgett and MacInnes, 1990; MacInnes et al, 1993; O'Donovan
and Wood, 1993; Scherly et al, 1993; Nouspikel and Clarkson,
1994; Shiomi et al, 1994) and maps to chromosome 13q32±33
(Takahashi et al, 1992). The XPG gene encodes a structure-speci®c
endonuclease that cleaves UV-damaged DNA approximately ®ve
nucleotides 3¢ to the site of the lesion and is also required
nonenzymatically for subsequent 5¢ incision by the XPF/ERCC1
heterodimer during the NER process (Aboussekhra et al, 1995; Mu
et al, 1996; Wakasugi et al, 1997). The XPG gene product has been
reported to be involved in the repair of oxidative DNA damage
(Cooper et al, 1997; Klungland et al, 1999; Le Page et al, 2000).
Recently, we characterized the genomic XPG gene architecture
(15 exons and 14 introns) and found six alternatively spliced XPG
mRNA isoforms in normal cells and tissues (Emmert et al, 2001).
Mutations in the XPG gene can result not only in the XP
phenotype but also in a phenotype that combines features of XP
and CS (XP/CS complex) (Rapin et al, 2000). The XP/CS
complex has been proposed as a distinct clinical entity (Robbins et
al, 1974; Robbins, 1988). XP/CS complex patients exhibit
developmental retardation, dwar®sm, and severe neurologic abnor-
malities plus sun sensitivity and other abnormalities of XP,
including skin cancer (Moriwaki et al, 1996; Rapin et al, 2000).
Only 10 patients who fall into the rare XP complementation
group G (XP-G) have previously been reported worldwide
(Table I) (Cheesbrough and Kinmont, 1978; Keijzer et al, 1979;
Arlett et al, 1980; Ichihashi et al, 1985; Norris et al, 1987; Jaeken et
al, 1989; Vermeulen et al, 1993; Hamel et al, 1996; Moriwaki et al,
1996; Lindenbaum et al, 2001; Zafeiriou et al, 2001). The molecular
defects in the XPG gene that account for the patients' clinical
symptoms have been analyzed in nine of the XP-G patients
(Nouspikel and Clarkson, 1994; Nouspikel et al, 1997; Okinaka et
al, 1997; Cleaver et al, 1999; Zafeiriou et al, 2001; Lalle et al, 2002).
Here, we describe three new patients from different ethnic
backgrounds in XP-G. Two patients, XP96TA and XP82DC,
had severe clinical symptoms suggestive of the XP/CS complex
phenotype. The third patient, XP65BE, exhibited very mild XP
symptoms with no neurologic abnormalities. In agreement with
earlier studies (Nouspikel et al, 1997; Cooper et al, 1997; Klungland
et al, 1999; Le Page et al, 1999), mutational analysis revealed that the
two XP/CS-like patients carried mutations that led to severely
truncated XPG proteins. The mildly affected XP-G patient carried
a XPG allele with a single amino acid mutation that retained partial
functional activity.
MATERIALS AND METHODS
Cell lines and culture conditions Primary normal ®broblasts
(GM03651C, GM03377B, AG06239, C5RO, CRL1876, FS, 86TA,
95TA, and 100TA), normal SV40-transformed ®broblasts (GM00637),
and XP-G ®broblasts from a patient with the XP/CS phenotype
(XP20BE±AG08803), from the three new XP-G patients (XP96TA±
GM16180, XP82DC±GM16181, and XP65BE±GM16398), from CS
patients (CS267BE±GM11551), and from XP-D patients (XP3TA,
XP45TA) were studied. Fibroblasts were cultured in Dulbecco's
modi®ed Eagle's medium supplemented with 2% glutamine and 10%
fetal bovine serum (FBS) (Invitrogen) in an 8% CO2 humidi®ed
incubator at 37°C. Lymphoblastoid cell lines were established from the
parents of XP65BE and used for DNA sequence analysis: mother
(XPH103BE±GM16023) and father (XPH104BE± GM16464). Blood
was obtained from both parents of XP96TA and the DNA extracted for
sequencing. All GM and AG cells were deposited in the Human Genetic
Mutant Cell Repository, Camden, NJ. TA cells originate at Tel Aviv
University. CRL cells were obtained from the American Type Culture
Collection, Rockville, MD. C5RO was a generous gift from J.
Hoeijmakers, Rotterdam, The Netherlands. These studies were
performed in accordance with protocols approved by the U.S. National
Cancer Institute, Armed Forces Institute of Pathology, and Tel Aviv
University Institutional Review Boards.
Post-UV cell survival Cell survival was determined by assessing cell
growth in 35 mm dishes after UVC irradiation as described previously
(Kraemer et al, 1989). A total of 2 3 104 cells were seeded per well and
irradiated with 0, 3, 6, 9, and 12 J per m2 UVC. UV was administered
using an integrating UV irradiator as described previously (Busch et al,










94RD27 0.6 yd/M No XP/CSe <4% + 10, 12
XPCS4RO 0.9 yd/F Yesf XP/CS 4%±7% + + 13
XPCS2LV 1.7 yd/M No XP/CS 5% +, + 6, 7, 12
XP82DC 5.8 yd/F No XP/CS <1% +, + This report
XP96TA 6 yd/F No XP/CS <1% + This report
XP20BE 6.1 yd/M No XP/CS 1% + 9, 11, 14
XPCS1LV 6.5 yd/F No XP/CS 5% + 6, 7, 12
XP3BR 6 y/M No Severeg 0% + I 3, 15
XP2BI 17 y/F No Yesh 2% + + 1, 2, 15
XP65BE 14 y/F No No 10% + + This report
XP124LOi 14 y/M No No 14% + + 5, 8
XP125LOi 15 y/F No No 15% + + 5, 8
XP31KO 37 y/F Yesj No 25% 4
aArranged by age at death and severity of neurologic symptoms.
bMeasured by unscheduled DNA synthesis or alkaline sucrose gradient analysis (% of normal).
cMutations in cited references: each + signi®es one mutation reported of indicated type; I indicates single base depletion with alternatively spliced insertion; blank space
signi®es no mutation reported.
dAge at death.
eXP/CS complex.
fClinical diagnosis of multiple small skin cancers on sun-exposed skin.
gSevere mental and growth retardation.
hDelayed onset of neurologic abnormalities (11 y).
iSiblings.
jBasal cell carcinoma.
k1, Cheesbrough and Kinmont (1978); 2, Keijzer et al (1979); 3, Arlett et al (1980); 4, Ichihashi et al (1985); 5, Norris et al (1987); 6, Jaeken et al (1989); 7, Vermeulen et
al (1993); 8, Nouspikel and Clarkson (1994); 9, Moriwaki et al (1996); 10, Hamel et al (1996); 11, Okinaka et al (1997); 12, Nouspikel et al (1997); 13, Zafeiriou et al
(2001); 14, Lindenbaum et al (2001); 15, Lalle et al (2002).
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1980) with calibration recently rechecked using a UV meter. After 4±6 d
the cells per well were counted when the most crowded wells had
reached about 50% con¯uence. Cell survival was calculated as the ratio
of cell numbers in irradiated versus unirradiated dishes. Survival
parameters were determined by plotting UV survival data on a semilog
plot and observing what exposures caused 37% and 10% survival. The
averages of four graphs were calculated. Alternatively, cell survival was
determined by post-UVC colony-forming ability as described previously
(Slor et al, 2000).
DNA repair measurements Measurement of post-UVC unscheduled
DNA synthesis was performed as described previously (Kraemer et al,
1975) with the following modi®cations. Fibroblasts were seeded into
two-well glass tissue culture chamber slides (eight slides per culture with
the best three slides used for grain counting), using 100,000 cells per
well in modi®ed Eagle's medium alpha with 20% FBS, replaced 1 d later
with 1% FBS medium to reduce cell division. Six days after inoculation,
cells were rinsed and refed with phosphate-buffered saline before
irradiation with 10 J per m2 of 254 nm UV from a germicidal mercury
UV lamp, immediately followed by 2 h incubation in 1% FBS medium
containing 10 mCi methyl-3H-thymidine per ml. After labeling, the cells
were ®xed with 3 parts methanol to 1 part acetic acid, rinsed, and had
unbound label removed using 5% saturated trichloroacetic acid.
Autoradiography was performed using Kodak NTB2 emulsion (50% in
water), followed by nuclear fast red staining of slides. For each culture, at
least 100 irradiated and 100 unirradiated nuclei were scored (»35 per
slide chamber). An additional method used to measure excision repair
was based on arresting repair with the chain terminating inhibitor
cytosine arabinoside. Cells were grown in [14]-CdThd (0.05 mCi per ml,
55 mCi per mmol) for 48 h, rinsed, irradiated with 13 J per m2, and
then grown for 4 h in cytosine arabinoside (10±5 M) and hydroxyurea
(10±3 M), after which the number of single strand breaks was determined
in alkaline sucrose gradients (Cleaver, 1981).
UV-induced inhibition of RNA synthesis Recovery of RNA
synthesis following UV exposure was measured by 3H-uridine
incorporation by autoradiography using the same methodology as for the
unscheduled DNA synthesis assay, with the following exceptions: (i)
labeling was with 3H-uridine, not 3H-thymidine; (ii) labeling was for
50 min, done 19 h 50 min following 5 J per m2 of UV; (iii) repair was
calculated as the ratio of grain counts (corrected for background) for
irradiated versus unirradiated nuclei, with the average of normal controls
(C5RO and CRL1876) de®ned as 100% of normal. Alternatively,
recovery of RNA synthesis 24 h following UV exposure was also
measured by 3H-uridine incorporation by scintillation counting as
described previously (Slor et al, 2000).
Northern blot analysis Total cytoplasmic RNA was isolated from
cells (RNAqueous-Midi Kit; Ambion) and Northern blotting was
performed following standard procedures as per the vendor's protocol
(Northern Max Kit, Ambion). For probing, XPG cDNA was released
from pXPG plasmid by Not I enzyme digestion, gel puri®ed, and 32P
labeled by random priming. Autoradiographic band intensities were
measured with a laser densitometer (Molecular Dynamics). After
stripping off the XPG probe (Strip-EZ DNA, Ambion), the same nylon
membrane was reprobed with b-actin cDNA (Clontech) as an internal
standard. The XPG mRNA levels were normalized to the levels of the
b-actin internal standards.
Plasmid host cell reactivation (HCR) and complementation group
assignment Either the pRSVcat plasmid (Protic-Sabljic and Kraemer,
1985) that contains the chloramphenicol acetyltransferase (CAT) reporter
gene or a luciferase reporter gene plasmid (pCMVLuc) were used to
measure post-UVC HCR. In the pCMVLuc plasmid construct the
original SV40 promoter of the luciferase gene containing pGL3 plasmid
(Promega) was replaced with a CMV promoter obtained from pRL
plasmid (Promega). HCR was performed as described previously
(Emmert et al, 2000). Brie¯y, 0.25 mg of CsCl-puri®ed and UVC-treated
or untreated pRSVcat or pCMVLuc plasmid was transfected into
0.15 3 106 ®broblasts by using 3 ml of lipofectamine (Gibco BRL) in a
total volume of 1 ml OPTI-MEM medium (Gibco BRL) for 5 h. After
48 h the CAT or luciferase activity and the total protein amount were
measured in the cell lysates. Relative CAT or luciferase activity is
expressed as percentage activity obtained from UVC-treated plasmids
compared with the corresponding untreated control plasmids. In order to
assign the XP65BE, XP96TA, and XP82DC ®broblasts to a speci®c XP
complementation group (Slor et al, 2000) a simultaneous cotransfection
was performed with 0.25 mg of a wild-type XP cDNA containing
plasmid (pXPA, pXPB, pXPC, pXPD, pXPF, pXPG) along with the
UV-irradiated or unirradiated reporter gene plasmid (Carreau et al,
1995).
RNA/DNA extraction, DNA ampli®cation, and nucleotide
sequence analysis RNA from cultured cells was isolated using the
RNAqueous-Midi Kit (Ambion). Two micrograms total RNA were
reverse transcribed using the Superscript preampli®cation system and
oligo (dT)12±18 primers for ®rst strand cDNA synthesis according to the
manufacturer's protocol (Gibco BRL). The entire 3.8 kb coding region
of the XPG gene was then ampli®ed with two primers UTR5¢ (forward)
and UTR3¢ (reverse) (Nouspikel et al, 1997) using the Advantage cDNA
PCR Kit (Clontech). The polymerase chain reaction (PCR) steps were
conducted as follows: 94°C for 1 min, then 35 cycles of ampli®cation
(94°C for 20 s and 71°C for 3 min), ending with 71°C for 3 min. After
agarose gel puri®cation the entire XPG cDNA was then subcloned and
sequenced. As controls genomic DNA was isolated from cultured cells
(DNAzol reagent, Gibco BRL) or from peripheral blood lymphocytes
(QIAamp Blood Kit, Quiagen) and subjected to sequencing. Sequencing
was performed by cycle sequencing employing dideoxy termination
chemistry and an ABI 373 A automated DNA sequencer (P.E. Applied
Biosystems, CA) using appropriate primers (Emmert et al, 2001).
XPG exon 12 restriction fragment length polymorphism (RFLP)
assay The G2817A polymorphism region in exon 12 of the XPG gene
was ampli®ed using a forward primer in exon 12, 2730±2747
(5¢-GGATTGGACCGGAATAAG-3¢), and reverse primer in intron 12,
K34 (5¢-TCACATGTTACAGCATGACAG-3¢). Using Advantage
cDNA PCR Kit (Clontech, CA) as per the manufacturer's protocol, the
PCR steps were conducted as follows: 94°C for 3 min, then 35 cycles of
ampli®cation (94°C for 20 s and 66°C for 3 min), ending with 66°C for
3 min. The genetic change G2817A was analyzed by Aci I restriction
endonuclease (New England Biolabs) digestion of the 247 bp PCR
Figure 1. Pedigrees of XP families. (A) Pedigree of family of
XP96TA. Six generations of this consanguineous family are shown.
Patient XP96TA (arrow) and her affected brother (solid symbols) died
before 2 y of age. The parents are obligate heterozygotes (half solid
symbols). (B) Pedigree of family XP65BE. Four generations of this family
are shown. Patient XP65BE (arrow) has an unaffected sister (open circle).
The parents are obligate heterozygotes (half solid symbols). Four relatives
have cancer (diagonal shading): MM, cutaneous melanoma; Breast Ca,
breast cancer; Throat Ca, throat cancer. Diagonal line indicates death.
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products ampli®ed from donor DNA using primer pair 2730±2747 and
K34. The G at position 2817 in exon 12 of the XPG creates an Aci I
site that is absent with A at 2817. Aci I digestion converts the 247 bp
PCR product into two fragments of size 86 bp and 161 bp. The
fragments were resolved on 2% agarose gel and photographed under UV
light after staining with ethidium bromide.
To assess the frequency of this newly identi®ed mutation in the XPG
gene we screened DNA from 104 anonymous donors (men and women
employees and unrelated children, age range 1±76 y) randomly selected
from National Institutes of Health, Bethesda, MD (Khan et al, 2000).
Buccal swab samples were obtained from each individual and genomic
DNA was extracted as described previously (Richards et al, 1993).
XPG allele-speci®c complementation assay In order to assess the
in vivo functional activity of the XPG missense mutation G2817A
(Ala874Thr) found in XP65BE cells an expression vector (pXPG-
G2817A) was constructed. A site directed mutagenesis kit (Stratagene)
and appropriate primers (forward, GTGGGTTGTGTAACCACCATG-
GAAATTCTC; reverse, GAGAATTTCCATGGTGGTTACACAACC-
CAC) were used for that purpose as per the vendor's protocol. We used
the plasmid HCR assay as described above to measure functional
correction of the XP-G DNA repair defect in living human cells by
cotransfection of the wild-type XPG (pXPG plasmid) or the mutated
XPG (pXPG-G2817A plasmid) forms of XPG cDNA into known XP-G
patient cells (XP20BE).
RESULTS
Case history An Israeli-Palestinian girl (XP96TA) was examined
at 11 mo of age in Israel. Her parents were related but clinically not
affected (Fig 1A). There was no known affected family member
over the last four generations. XP96TA presented clinically with
XP symptoms of freckling in the sun-exposed areas of the skin,
Figure 2. XP-G patients XP82DC and XP65BE. Upper left: Patient XP82DC at 3 y of age has deep-set eyes characteristic of CS and irregular
lentiginous pigmentation on her face characteristic of XP indicating the XP/CS complex. Lower left: Patient XP82DC at 3 y has characteristic XP
pigmented lesions present on her forearms and dorsa of hands along with thin, translucent skin with readily visible veins. The small size of her hands is
apparent in comparison to the hands of her mother. Middle column, top: Patient XP65BE at age 6 mo experienced severe sunburn of her face on
minimal sun exposure. Erythema and swelling is seen on the skin of forehead, cheeks, and periorbital area. Middle column, middle: Patient XP65BE at
age 9 mo shows erythema and peeling of skin of the malar area of the face following sun exposure. Middle column, bottom: Patient XP65BE at age 4.5 y
shows pigmentary changes on her nose, malar area, and other portions of the face. Upper right: Patient XP65BE at age 4.5 y shows blistering sunburn
on upper thigh. Note spared area above the knee where sunscreen was applied. Lower right: Patient XP65BE at age 14 y shows minimal pigmentary
changes on face and sparing of neck and hand. She used measures to protect her skin from sun exposure.
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predominantly on the face. The patient had additional CS-like
symptoms including low birth weight and failure to gain weight,
microcephaly, small stature and developmental delay, and a bird-
like face with deep-set eyes. Brain scans were not performed. Due
to progressive cachexia she died at age 6 y. XP96TA also had an
affected brother with similar clinical symptoms who died at 2 y of
age. Neither sibling had an autopsy. Another sibling was healthy.
A Caucasian girl (XP82DC) was examined in Buffalo, NY, and
Gulfport, MS. Her parents were clinically normal and not related.
At the age of 3 y XP82DC presented with combined features of the
XP and CS phenotypes (Fig 2, upper and lower left). She had
extreme sun sensitivity and freckling on the face and dorsal
forearms. She also developed some actinic keratoses, precursors of
squamous cell carcinoma. She developed her ®rst sunburn at 2 wk
of age as a result of sleeping beside a closed window with sunlight
streaming through. Although the parents tried to avoid sun
exposure she experienced numerous sunburns as a result of even
the briefest exposure to sunlight. In addition, she showed
progressive neurologic impairment. She had a short stature,
microcephaly, a bird-like face with deep-set eyes, was unable to
walk or crawl, and could barely verbalize words like mama or dada.
At 12 mo unenhanced CT scan of the brain was normal with no
evidence of calci®cations. She had progressive weight loss and
cachexia and died at 5.8 y of age with acute liver failure thought to
be related to a viral infection. An autopsy was not performed.
A 14-y-old Caucasian girl (XP65BE) was referred to the
National Institutes of Health because of severe sun sensitivity.
Her parents were clinically normal, not consanguine, and have
another healthy daughter (Fig 1B). Her maternal aunt had a history
of melanoma and her maternal great uncle was reported to have
died from melanoma in his 70s. Two other relatives had cancer
(Fig 1B). The parents reported that XP65BE ®rst developed a
severe sunburn at the age of 6 mo after minimal exposure to
sunlight (Fig 2, middle column, top). Redness and swelling peaked
24±36 h after sun exposure and persisted 5±6 d. The patient had
about a half dozen separate episodes of severe sun reactions (Fig 2,
middle column) despite the parents' strong efforts to protect her with
sunscreens and long-sleeved clothing. Except for some mild
freckling on her cheeks, nose, and lips and a pterygium of her
right eye, at age 14 y she presented no other XP symptoms (Fig 2,
lower right). She has not developed skin neoplasms and examination
of her hair shafts with a polarizing microscope did not show ``tiger
tail'' banding characteristic of trichothiodystrophy. She is an honor
roll student in high school, performs in school musicals, and takes
ballet lessons. She had a normal audiogram and a normal neurologic
exam with no signs of neurologic impairment such as diminished
deep tendon re¯exes or microcephaly. MRI was normal with no
evidence of dilated ventricles of the brain.
Reduced post-UV cell survival, DNA repair, and RNA
synthesis Post-UV cell survival of XP65BE and XP82DC
®broblasts was assessed and compared to four normal cell strains
using a growth inhibition assay (Fig 3A). The D37 (dose that results
in 37% cell survival) was 4±8 J per m2 for the four normal controls
and the D10 was 10±17 J per m
2. In contrast, the D37 for XP82DC
cells was 0.6 J per m2 and the D10 was 1.2 J per m
2, representing
about 7±8 3 normal sensitivity. For XP65BE cells, the D37 was
1.6 J per m2 and the D10 was 3.3 J per m
2, indicating about 3 3
normal sensitivity. Thus, although hypersensitive to UV, the
XP65BE cells were less sensitive than XP82DC cells. Post-UV cell
survival of XP96TA was similarly much less than that of normal
cells and was similar to that of an XP-D cell strain using a colony-
forming assay (Fig 3B).
Post-UV DNA repair in XP65BE, XP96TA, and XP82DC cells
was compared to normal cells and to XP20BE (XP-G) cells
Figure 3. Characteristics of XP ®broblasts
studied. (A) Post-UV cell survival ± growth
inhibition assay. (B)Post-UV cell survival ±
colony-forming ability assay. (C) Post-UV DNA
repair assays. NER activity was assessed in
cultured ®broblasts by measuring UV-induced
incorporation of tritiated thymidine in auto-
radiograms (XP96TA, XP82DC, and XP20BE)
and by detecting DNA strand breaks in alkaline
sucrose gradients (XP65BE). DNA repair levels
are expressed as percentage compared to normal
cells. (D) Post-UV RNA synthesis recovery.
RNA synthesis was assessed in cultured ®broblasts
by measuring UV-induced incorpora-tion of
tritiated uridine in autoradiograms 24 h after UV
exposure. (E) Northern blot analysis of XPG
mRNA expression. 25 mg of total RNA isolated
from GM00637 cells (normal, lane 1), XP65BE
cells (lane 2), XP96TA cells (lane 3), and XP20BE
cells (XP-G/CS control, lane 4) were loaded per
lane, separated by electrophoresis, transferred to a
nylon membrane, and probed with a radiolabeled
3.8 kb XPG cDNA fragment. The relative
amount of RNA transferred was moni-tored by
probing with b-actin cDNA, which was used to
normalize the XPG mRNA levels.
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(Fig 3C). Using autoradiography C5RO and CRL1876 had a
combined mean of 82.3 UV-induced grains per nucleus and
XP96TA had ±0.3 UV-induced grains per nucleus. In another
experiment C5RO and CRL1876 had a mean of 71.6 UV-induced
grains per nucleus and XP82DC had 0.3 UV-induced grains per
nucleus. This unscheduled DNA synthesis of less than 1% of normal
is characteristic of a severe form of the NER defect of XP. In
contrast, XP65BE had DNA repair levels of about 10% of normal
cells, based on alkaline sucrose gradient analysis. Although mark-
edly reduced, this result is indicative of at least some residual
functional NER activity in this patient.
RNA synthesis is inhibited by UV radiation in human cells.
Recovery from this inhibition was measured in normal cells
(C5RO and CRL1876) by autoradiography. Recovery was found
to be slower in XP65BE cells (9.4% of normal) and from a patient
with CS (CS267BE) 27.1% of normal as a positive control
(Fig 3D). In another experiment XP96TA showed 9% of
unirradiated RNA synthesis at 24 h, which was similar to the 8%
seen in an XP3TA (XP-D) cell strain. These results were much
lower than the 80% seen in the normal control (95TA) (scintillation
counting method ± data not shown). These ®ndings are charac-
teristic of CS cells and of XP cells in complementation groups A,
D, and G, but not XP-C (Van Steeg and Kraemer, 1999).
XPG mRNA levels correlate with the severity of clinical XP
symptoms We utilized northern blot hybridization to compare
the XPG mRNA expression levels in XP65BE and XP96TA cells
with those in normal cells and in cells from another XP-G/CS
complex patient (XP20BE) (Moriwaki et al, 1996; Rapin et al,
2000) (Fig 3E). XPG cDNA was used as a probe and a single band
about 3.8 kb in size was detected in the normal control cells
(Fig 3E, lane 1). In marked contrast, XPG mRNA was barely
detectable in XP96TA and XP20BE XP-G/CS control cells
(Fig 3E, lanes 3, 4). Cells from the clinically mildly affected
XP65BE patient, however, had nearly normal XPG mRNA
expression levels (90% compared to normal cells when normalized
to the b-actin standard) (Fig 3E, lane 2). Hybridization of the same
membrane with b-actin cDNA probe (Fig 3E, bottom) revealed
similarly high b-actin mRNA levels in all four samples indicating
that the differences in the steady-state levels of XPG mRNA were
not because of degradation of RNA samples isolated from the cell
lines.
HCR and assignment to XP-G We utilized the HCR assay to
study cellular DNA repair capacities in vivo and for
complementation group assignment. This assay measures the
ability of the host cells to repair UV-damaged plasmid DNA by
assessing the recovery of a reporter gene expression, measured
indirectly as enzyme activity of the CAT or luciferase reporter
gene. UV-treated and untreated pRSVcat plasmid (Protic-Sabljic
and Kraemer, 1985) containing the CAT reporter gene or
pCMVLuc plasmid (Slor et al, 2000) containing the ®re¯y
luciferase reporter gene was used for that purpose. All patient
®broblasts XP96TA (Fig 4, top), XP82DC (Fig 4, middle), and
XP65BE (Fig 4, bottom) showed a low relative reporter gene
indicating the reduced DNA repair capacity for DNA
photoproducts in these cells. Normal repair-pro®cient ®broblasts
typically result in 20%±50% reporter gene expression at 1000 J per
m UVC (data not shown).
Cotransfection of the UV-irradiated reporter gene plasmid with
plasmids that carry cloned wild-type XP cDNA (pXPA, pXPB,
pXPC, pXPD, or pXPF) (Carreau et al, 1995) did not alter the
reduced reporter gene expression. In contrast cotransfection of the
XPG cDNA containing plasmid resulted in enhanced reporter gene
activities indicating that XPG cDNA could complement the
cellular DNA repair defect. This clearly assigns XP65BE, XP96TA,
and XP82DC cells to XP-G (Fig 4).
Sequence analysis of the individual XPG gene defects To
identify the molecular defects in the XPG gene, mRNA isolated
from patients' ®broblasts was reverse transcribed and the entire
3.8 kb XPG cDNA was sequenced after PCR ampli®cation, gel
puri®cation, and subcloning (single allele sequencing) (data not
shown). Genomic DNA from the ®broblasts was isolated and
selected portions of the XPG gene were sequenced to verify the
mutations found in the cDNA (combined maternal and paternal
allele sequencing). Figure 5 shows results obtained from genomic
DNA.
XP82DC, a severely affected XP/CS complex Caucasian girl,
was a compound heterozygote for a nonsense and a frameshift
mutation. One allele (Fig 5, XP82DC1) carried a transition
mutation of C to T at nucleotide 243 in exon 1. This nonsense
mutation changed amino acid 16 from glutamine (CAG) to an early
termination signal (TAG). The other allele (Fig 5, XP82DC2) had
a deletion of two bases (T, G) at nucleotides 2801±2804 in exon 12.
This two-base deletion led to a frameshift at amino acid position
869 and to the creation of a new termination signal (TGA) 10
codons downstream. Thus, both mutations would be predicted to
Figure 4. HCR and assignment to XP-G. A 1000 J per m2 UVC-
treated reporter gene plasmid (pRSVcat or pCMVLuc) was either
transfected alone (open triangle) or cotransfected with an XP cDNA
containing plasmid [pXPA (open circle), pXPB (triangle), pXPC (diamond),
pXPD (inverted triangle), pXPF (cross), pPXG (closed circle)] into triplicate
cultures of primary patient ®broblasts. Each symbol represents the relative
reporter gene activity in an independent transfection experiment 48 h
after transfection compared with the corresponding unirradiated control
reporter gene plasmid. Top: XP96TA host cells. Middle: XP82DC host
cells. Bottom: XP65BE host cells.
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lead to severely truncated XPG proteins. No material from either of
the patient's parents was available for analysis.
XP96TA, the severely affected XP/CS complex Israeli-
Palestinian girl, was homozygous for a deletion of two bases (T,
C) at nucleotides 1116±1120 in exon 8 (Fig 5, XP96TA1,2). This
two-base deletion led to a frameshift at amino acid position 308 and
to the creation of a new termination signal (TGA) 12 codons
downstream, thus resulting in a severely truncated XPG protein.
Sequencing DNA from her parents revealed that they were both
heterozygous for the same frameshift mutation as expected by the
history of consanguinity (Fig 1A).
XP65BE, the mild XP-G female patient, was a compound
heterozygote harboring different mutations in each XPG allele.
One allele (Fig 5, XP65BE1) carried a transition mutation of C to
T at nucleotide 603 in exon 4. This nonsense mutation changed the
amino acid 136 from glutamine (CAA) to an early termination
signal (TAA), which is predicted to lead to a severely truncated
XPG protein. This mutation was inherited from the patient's father
as assessed by sequencing of genomic DNA from the father. The
other allele (Fig 5, XP65BE2) carried a transition mutation of G to
A at nucleotide 2817 in exon 12. This missense mutation resulted
in an amino acid change at 874 from alanine (GCC) to threonine
(ACC). This mutation was veri®ed in genomic DNA obtained
from the patient's mother by sequencing (data not shown). We
developed an RFLP assay utilizing PCR with primers ¯anking
exon 12 and digestion with Aci I. Aci I digestion of G/G DNA
yields two bands of 86 and 161 bp, A/A DNA is resistant to
digestion yielding a single 247 bp band, and G/A heterozygotes
yield all three bands (Fig 6B). Cells from XP65BE and her mother
were heterozygous for the G2817A mutation whereas cells from a
normal donor (AG06239) and the father were homozygous for G/
G (Fig 6A).
In order to determine if the XPG G2817A mutation was a
common polymorphism, we screened DNA obtained from buccal
swabs of 104 anonymous donors (men and women employees and
unrelated children, age range 1±76 y) randomly selected from
National Institutes of Health, Bethesda, MD (Khan et al, 2000).
The RFLP assay showed the normal G/G genotype for all 104
donors indicating that the XPG G2817A mutation was not a
common polymorphism (data not shown).
Partial functional activity of the Ala874Thr missense
mutation in XP65BE All three mutations identi®ed in the
severely affected XP96TA and XP82DC patients are predicted to
result in severely truncated (and potentially nonfunctional) XPG
proteins (Fig 5). In contrast, in addition to a nonsense mutation in
exon 4, the mildly affected XP65BE patient also carried one XPG
allele with a single amino acid change (Ala874Thr). To determine
the functional consequence of this single amino acid change for
NER in vivo we constructed a new expression vector (pXPG-
G2817A) utilizing site-directed mutagenesis to introduce this
missense point mutation into the wild-type XPG cDNA of the
pXPG expression vector. We used the HCR-based
complementation assay as described above to test the allele-
speci®c ability to complement the NER defect in known XP-G
cells. The XPG-G2817A cDNA exhibited reduced functional
Figure 5. Mutational analysis of XPG in XP65BE, XP96TA, and XP82DC cells. The structural map of the XPG gene visualizes the location of
the mutations found (top). The 15 exons and 14 introns are numbered and their size in base pairs is indicated below. Each mutation in the two XPG
alleles found in each of these XP-G patients is listed (middle) and graphically visualized (bottom). The graphic inserts represent sequencing results from
genomic DNA (mix of maternal and paternal alleles). Two inserts show reverse sequences. Results were also veri®ed by sequencing of cDNA obtained
from reverse-transcribed mRNA.
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activity compared to wild-type XPG cDNA, but could partially
complement the NER defect of XP-G cells (Fig 6C). Transfection
of normal repair-pro®cient cells with wild-type XPG or XPG-
G2817A cDNA did not alter the ability to repair a UV-damaged
reporter gene plasmid (Fig 6D). Thus, overexpression of XPG-
G2817A cDNA did not have a dominant negative effect on the rate
of NER in normal cells.
DISCUSSION
XP and CS comprise distinct clinical entities (Bootsma et al, 1998).
Both disorders are characterized by sun sensitivity. About 20% of
XP patients have microcephaly, deafness, and progressive neuro-
logic degeneration, features that are also present in CS (Rapin et al,
2000). Typical XP symptoms include early onset of freckling and
skin cancer in parts of the body exposed to UV radiation (Kraemer
and Slor, 1985; Bootsma et al, 1998). If neurologic abnormalities
are present, they include decreased to absent deep tendon re¯exes
and primary neuronal degeneration (Rapin et al, 2000). The XP
phenotype can be caused by a mutation in one of the seven XP
genes (XPA±XPG), which results in defective NER. NER
eliminates a wide variety of DNA damage including UV-induced
DNA photoproducts (De Laat et al, 1999). The XP-G comple-
mentation group is extremely rare with only 10 patients described
in the literature (Table I).
CS patients differ from XP. They show postnatal growth failure
leading to severe cachexia, dwar®sm, progressive pigmentary
retinopathy, and other ocular abnormalities such as cataracts and
optic disk atrophy. CS patients have normal or increased deep
tendon re¯exes, and signs of primary demyelination (tigroid
leukodystrophy) often associated with calci®cation of the brain
(Cantani et al, 1987; Nance and Berry, 1992; Moriwaki et al, 1996;
Stefanini et al, 1996; Rapin et al, 2000). The CS phenotype can
result from a mutation in either of the two CS genes (CSA or
CSB). These may result in defective transcription-coupled repair
predominantly of oxidative DNA damage or subtle defects in basal
transcription (Stefanini et al, 1996; Le Page et al, 2000).
Some patients have been identi®ed who exhibit combined
features of XP and CS (XP/CS complex) including pigmentary
cutaneous symptoms together with one or more of the character-
istic features of CS (Rapin et al, 2000). Surprisingly, the 10 patients
who were identi®ed as having the XP/CS complex to date had
defects in three different XP genes (XPB, XPD, or XPG). Three
XP/CS patients were assigned to XP-B (XP11BE, XPCS1BA, and
XPCS2BA), two XP/CS patients to XP-D (XPCS2 and XP8BR),
and ®ve XP/CS patients to XP-G (94RD27, XPCS4RO,
XPCS2LV, XP20BE, and XPCS1LV) (Table I) (Robbins et al,
1974; Cleaver et al, 1999). These patients generally have the
cutaneous and cellular abnormalities of XP including increased
cancer susceptibility and the neurologic features of CS (Moriwaki et
al, 1996; Rapin et al, 2000; Lindenbaum et al, 2001). Thus, certain
mutations in these XP genes may result in both XP and CS
symptoms.
Here we report three new XP patients (Table I). XP82DC, a
Caucasian girl, and XP96TA, an Israeli-Palestinian girl, exhibited
severe clinical symptoms typical for XP/CS complex. In contrast
XP65BE, a 14-y-old Caucasian female, presented with mild XP
symptoms (Fig 2). To our surprise and despite the patients' clinical
heterogeneity XP65BE, XP96TA, and XP82DC could all be
assigned to XP-G (Fig 4). For that purpose we used a rapid HCR-
based complementation assay (Carreau et al, 1995; Khan et al,
1998). The HCR assay uses plasmids containing a reporter gene to
monitor the DNA repair activity in DNA repair de®cient cells
(Protic-Sabljic and Kraemer, 1985; Runger et al, 2000). The
complementation assay utilizes expression vectors containing a
reporter gene, either the CAT or the luciferase gene, in a
cotransfection experiment with a repair vector expressing a normal
cloned human DNA repair cDNA (XPA, XPB, XPC, XPD, DDB/
XPE, XPF, or XPG). Repair de®cient XP cells show low post-UV
marker gene expression that is increased by cotransfection with the
wild-type cDNA of the appropriate complementation group.
Reliable results can be obtained within 48 h with this assay.
Molecular studies on primary ®broblasts isolated from these
patients revealed very low post-UV cell survival and very low UV-
induced DNA repair levels (Fig 3A, B, C, Table I). These are
typical features of most XP cells. There is marked clinical
heterogeneity in the XP-G complementation group ranging from
severe XP-G/CS complex to cutaneous involvement without
neurologic disease. There appears to be a relationship with the
severity of the neurologic involvement, length of life, and the level
of residual DNA repair activity among the XP-G patients. The
post-UV cell survival of the mildly affected XP65BE patient was
higher than that of the severely affected XP82DC patient with
Figure 6. RFLP detection and functional properties of the XPG-
G2817A single amino acid missense mutation found in XP65BE.
(A) DNA extracted from cultured cells from XP65BE, her parents, and
normal ®broblasts (AG06239) was used in a PCR employing primers
that ¯ank the exon 12 region in the XPG gene. The product was
subjected to electrophoresis on a 2% agarose gel with (+) or without (±)
digestion with Aci I. (B) The undigested product is 247 bp whereas Aci I
digestion converts the product with G at nucleotide 2817 to two
fragments of 86 and 161 bp. The product containing A at 2817 is
resistant to Aci I digestion. Thus donors of genotype G/G have two
bands (at 86 and 161 bp), and G/A heterozygotes have three bands (86,
161, and 247 bp). Cells from XP65BE and her mother were
heterozygous for the G2817A mutation. (C) UV-irradiated pCMVLuc
plasmid was transfected together with empty vector pcDNA3.1 (diamond)
or with a plasmid containing wild-type XPG cDNA (circle) or mutated
XPG-G2817A cDNA (triangle) into triplicate cultures of XP-G cells
(XP20BE). The XPG-G2817A cDNA retained partial functional activity.
(D) UV-irradiated pCMVLuc plasmid was transfected either alone
(inverted triangle) or together with a plasmid containing wild-type XPG
cDNA (circle) or mutated XPG-G2817A cDNA (triangle) into triplicate
cultures of normal repair-pro®cient cells (GM00637). Overexpression of
the XPG mRNAs did not positively or negatively in¯uence the cells'
ability to repair UV-damaged plasmid DNA. Each symbol represents the
relative luciferase activity in an independent transfection experiment 48 h
after transfection compared with the corresponding unirradiated control
pCMVLuc plasmid.
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neurodegeneration (Fig 3A). Post-UV colony-forming ability of
the severely affected XP96TA was similar to that of an XP-D
patient (Fig 3B). Post-UV colony-forming ability of the ®rst XP-
G patient described, XP2BI (Cheesbrough and Kinmont, 1978;
Keijzer et al, 1979) (Table I), was reported to be similar to that of
XP-D cells (Barrett et al, 1981). In addition, the severely affected
XP-G patients had extremely low DNA repair levels reported by
different laboratories (Table I). Five patients had features of XP/
CS complex: XPCS1LV and XPCS2LV (Jaeken et al, 1989;
Vermeulen et al, 1993), 94RD27 (Hamel et al, 1996), XP20BE
(Moriwaki et al, 1996; Lindenbaum et al, 2001), and XPCS4RO
(Zafeiriou et al, 2001) (Table I). Two of our patients XP96TA and
XP82DC also had features of the XP/CS complex. All seven of
these XP-G/CS patients died by age 7 y (Table I). In addition, the
second reported XP-G patient (XP3BR) was described as having
severe mental and growth retardation (Arlett et al, 1980) with low
DNA repair (Table I). Three of the XP-G patients, XP125LO,
her affected brother XP124LO, and XP31KO, had mild cutaneous
changes and no neurologic abnormalities (Ichihashi et al, 1985;
Norris et al, 1987). In addition, our patient XP65BE had mild
cutaneous disease without neurologic abnormalities. These four
XP-G patients without neurologic disease all lived at least 14 y and
had low DNA repair levels that were somewhat higher than those
of the patients with severe neurologic disease and early death
(Table I).
This degree of clinical heterogeneity is astonishing and not fully
understood. It is argued that mildly affected XP-G patients may
possess some residual NER activity and that the XP-G/CS patients
may have mutations that inactivate a second XPG gene function
(Nouspikel and Clarkson, 1994; Nouspikel et al, 1997).
Only 10 different mutations in eight XP-G patients were
previously reported (summarized in Cleaver et al, 1999; Lalle et al,
2002) (Table I). Our results add additional strong evidence to the
notion that mutations in the XPG gene can phenotypically result in
great clinical heterogeneity. We identi®ed ®ve new causative
mutations in the XPG gene in three new XP-G patients (Fig 5).
The severely affected XP-G/CS patients XP96TA and XP82DC
carried three different mutations that are predicted to lead to early
truncation of XPG protein translation. XP96TA, a daughter from
consanguine Israeli-Palestinian parents, was homozygous for a
frameshift mutation at amino acid 308 generating a new termin-
ation signal at amino acid 320 (exon 8). XP82DC was a compound
heterozygote for a frameshift mutation at amino acid 869
generating a new termination signal at amino acid 879 (exon 12)
and for a single base change mutation changing amino acid 16
(glutamine) into a stop codon (exon 1). Thus, XPG protein
truncations at exons 1, 8, and 12 led to severe combined XP and
CS symptoms (Fig 5). This would be in good agreement with the
other four nonsense mutations found in previously described
severely affected XP-G patients, which also led to protein
truncation. XP20BE, XPCS1LV, XPCS2LV, and 94RD27 had
frameshift mutations or amino acid changes that led to XPG protein
truncations at exons 1, 7, 9, and 13 (Nouspikel et al, 1997; Okinaka
et al, 1997) (Table I).
In its conserved N-terminal region and internal (I-) region
(includes exons 11 and 12) the XPG protein shares similarity in
sequence with a family of other nucleases. These include the
bacteriophage T4 RNase H and T5 D15 proteins, as well as the 5¢
to 3¢ exonuclease domains of eubacterial DNA polymerases
(Constantinou et al, 1999). Eukaryotic family members include a
family of small replication and repair nucleases (mammalian FEN-
1/DNase IV, Saccharomyces cerevisiae Rad27, and Schizosaccharomyces
pombe rad2) and larger proteins (vertebrate XPG, S. cerevisiae Rad2,
and S. pombe rad13) involved in NER (Constantinou et al, 1999).
All the early protein truncation mutations described above in
severely affected patients lack the putative bipartite nuclear
localization signal (Knauf et al, 1996; Park et al, 1996) or the
basic C-terminus, which are located further downstream (Scherly et
al, 1993). Loss of the nuclear localization signal could lead to
functional inactivation (Knauf et al, 1996; Park et al, 1996).
Alternatively, the loss of just the C-terminus may be the critical
event, because such a deletion was demonstrated to inactivate S.
cerevisiae RAD2 (Madura and Prakash, 1986).
Another reason for loss of protein function may result from the
strong downregulation of XPG gene expression. Northern blot
analysis revealed nearly undetectable XPG mRNA levels in
XP96TA and XP20BE cells (Fig 3E). Low levels of mRNA
expression are often associated with mutations that result in
production of truncated proteins. This process has been called
nonsense-mediated message decay (Nagy and Maquat, 1998). Cells
from XP-C patients were shown to have low XPC mRNA levels
in association with putatively truncated XPC protein (Slor et al,
2000). Interestingly, the mildly affected XP65BE patient had about
90% of XPG mRNA expression compared to normal. This suggests
that at least one XPG allele in this patient is not severely disrupted.
The other two mild XP-G siblings XP124LO and XP125LO also
had detectable amounts of XPG protein expression by Western blot
analysis (Nouspikel et al, 1997).
Our sequencing analysis of the mildly affected XP65BE girl
revealed two different causative mutations in the two XPG alleles
(Fig 5) (Table I). One mutation was a single base substitution
mutation (C603T) that changed the amino acid glutamine into a
termination codon (TAA) at amino acid position 603 (exon 4).
This mutation was inherited from her clinically unaffected father
who was found to be heterozygous for that mutation. As described
above this nonsense mutation would result in a severely truncated
and nonfunctional XPG protein. The second XPG allele from
XP65BE, however, only carried a missense mutation (G2817A)
that leads to a single amino acid change from alanine to threonine at
position 874 in exon 12. This amino acid change was also detected
in the patient's mother who was heterozygous (Fig 6A) and
clinically healthy. Based on the clinical outcome we would predict
that this Ala874Thr amino acid change disables some XPG
function(s), but retains some residual functional activity compared
to the mutations that lead to protein truncation. The Ala874Thr
mutation is located in the highly conserved I-region of the XPG
gene that is a member of the RAD2 family (Nouspikel and
Clarkson, 1994). There is evidence that the I-region is part of the
endonuclease active site of XPG (Nouspikel and Clarkson, 1994;
Nouspikel et al, 1997; Constantinou et al, 1999). Moreover the
causative missense mutation Ala792Val found in the only other
known mildly affected XP-G siblings XP124LO and XP125LO is
also located in this I-region 82 amino acids upstream of the
Ala874Thr mutation (Nouspikel and Clarkson, 1994; Nouspikel et
al, 1997). Fibroblasts from XP125LO were unable to remove UV-
induced pyrimidine dimers from either strand of an active gene
(Nouspikel et al, 1997). Puri®ed XPG protein with the Ala792Val
mutation found in cells from this patient, however, had low but
signi®cant 3¢ incision activity on a cisplatin-containing substrate in
a reconstituted system (Constantinou et al, 1999). Consistent with
the latter result, XP125LO lymphoblasts were signi®cantly more
UV resistant than lymphoblasts from a severely affected XP-G
patient in a thymidine uptake assay (Constantinou et al, 1999).
Moreover, when the Ala792Val protein was expressed in
lymphoblasts from this severely affected XP-G patient, it increased
their UV resistance up to the XP125LO level (Constantinou et al,
1999). XP2BI has an Leu858Pro mutation in the I-region that has
greatly impaired XPG endonuclease activity and provides a slight
increase in UV resistance to XPG-defective cells (Lalle et al, 2002).
These results suggested some residual repair capacity was retained
in the Ala792Val XPG allele. We found that the Ala874Thr cDNA
is functionally compromised but retained some activity with respect
to repair of UV-induced plasmid DNA damage (Fig 6) as expected
from the phenotype and inheritance of XP65BE and previous
reports (Nouspikel and Clarkson, 1994; Nouspikel et al, 1997;
Constantinou et al, 1999). In addition, no dominant negative effect
was found when the cDNA was overexpressed in normal cells
(Fig 6). A similar situation exists for XP-A. The neurologic
degeneration of XP-A occurs in patients with both mutations in the
DNA binding region (Satokata et al, 1992). Compound hetero-
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zygotes with one mutation in the DNA binding region and one
outside this region in the C-terminus, however, had no
neurodegeneration up to at least the age of 10±12 y (Cleaver et
al, 1995).
In conclusion we present strong evidence that XPG mutations
that are predicted to lead to truncated XPG proteins result in severe
neurodegeneration and clinical phenotypes with features of XP and
CS presumably due to complete loss of gene function. These
functions include NER capability (XP symptoms) (Van Steeg and
Kraemer, 1999) as well as transcription-coupled repair of oxidative
DNA damage (Cooper et al, 1997; Le Page et al, 2000) and repair of
oxidative DNA damage in the total genome (CS symptoms)
(Cooper et al, 1997; Klungland et al, 1999; Le Page et al, 2000). In
contrast, missense mutations in the I-region of XPG that allow
production of full-length XPG protein result in mild clinical XP
phenotypes probably due to the fact that these proteins retain some
residual NER capability and the full capability to repair oxidative
DNA damage.
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